Long lasting complete response with immunotherapy in a metastatic bladder carcinoma: a case report
Denise S T Magalhães1, Helena M Magalhães1, Alexandra S A Mesquita1
1Department of Medical Oncology, Hospital Pedro Hispano, Matosinhos Local Health Unit of Matosinhos, Matosinhos, Portugal.
Abstract:
At diagnosis, approximately 25% of urothelial carcinoma are invasive and only 15% of stage IV are alive at 5-years. We report a case of a 69-year-old woman with oligometastatic bladder cancer, treated with Atezolizumab in first-line, achieving a complete response after 4 cycles. Presently, the patient has an overall survival and progression free survival of 26 months with an improvement in her quality of life. Therefore, immunotherapy seems to be a promising treatment in advanced urothelial carcinoma. The previously performed radiotherapy, in association with a good performance status and oligometastatic disease, might have contributed to this admirable outcome.
